CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma

Authors :: Dimo Dietrich
Lutz Trojan
Niklas Klümper
Damian J Ralser
Romina Zarbl
Glen Kristiansen
Marieta Toma
Manuel Ritter
Michael Hölzel
Jörg Ellinger
Markus Eckstein
Danijel Sikic
Katrin Schlack
Andres Jan Schrader
Marc Rehlinghaus
Michèle J Hoffmann
Günter Niegisch
Annemarie Uhlig
Julie Steinestel
Konrad Steinestel
Ralph M Wirtz
Sebastian Strieth
Source :: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Publication Year :: 2021
Publisher :: BMJ Publishing Group, 2021.

Subjects :: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Full Text Access

Tools